Skandinaviska Enskilda Banken AB publ Sells 84,796 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Skandinaviska Enskilda Banken AB publ reduced its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 57.7% in the 4th quarter, Holdings Channel reports. The fund owned 62,041 shares of the biopharmaceutical company’s stock after selling 84,796 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Revance Therapeutics were worth $190,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of RVNC. Alpine Associates Management Inc. bought a new stake in shares of Revance Therapeutics in the third quarter worth about $21,605,000. Oddo BHF Asset Management Sas bought a new stake in shares of Revance Therapeutics in the third quarter worth about $3,763,000. Wellington Management Group LLP bought a new stake in shares of Revance Therapeutics in the third quarter worth about $2,315,000. Exome Asset Management LLC acquired a new position in shares of Revance Therapeutics during the third quarter worth about $1,804,000. Finally, Candriam S.C.A. acquired a new position in shares of Revance Therapeutics during the fourth quarter worth about $909,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RVNC shares. StockNews.com started coverage on Revance Therapeutics in a research report on Tuesday. They set a “hold” rating for the company. Mizuho reduced their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Barclays reduced their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ RVNC opened at $3.65 on Wednesday. The stock has a 50 day moving average price of $3.60 and a 200 day moving average price of $4.29. Revance Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $6.65. The stock has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.